Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AdvaMed's Next Chairman Is Abbott Exec Jim Mazzo

This article was originally published in The Gray Sheet

Executive Summary

Abbott Medical Optics' chief exec Jim Mazzo is on deck to be the next chairman of AdvaMed, succeeding the outgoing Michael Mussallem

You may also be interested in...

China Is Top International Priority For AdvaMed's New Chairman

U.S. medical device association AdvaMed's new chairman, Jim Mazzo, cites regulatory roadblocks in China as the most important international marketing issue facing U.S. device manufacturers

FDA Hints At Possible 510(k) Tweaks At Public Meeting

FDA is considering changing how predicate devices are selected for 510(k) submissions and beefing up its post-market authorities for 510(k)-cleared products, agency reps suggested at a Feb. 18 public meeting

Could Revisiting US Approval Decisions Become Less Rare?

While not identifying specific situations raising potential questions, the FDA commissioner uses his appearance at agency's annual rare disease event to advise regulatory decisions may be revisited as more data becomes available. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts